The patent refers to SciSparc’s innovative combination therapy of N-Acylethanolamines and Clearmind’s MEAI, (5-methoxy-2-aminoindane) addressing binge behaviour, including alcohol consumption, eating, ...

Clearmind Medicine (CMND) announced a patent publication by the Instituto Mexicano de la Propriedad Industrial, the National Mexico Patent ...

Vancouver, Canada, Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel ...

Arialief is a comprehensive nerve health supplement that specifically targets sciatic nerve pain and claims to provide ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Misregulation of protein–protein interactions (PPIs) underlies many diseases; hence, ...

The therapy involves the use of MEAI and N-Acylethanolamines, which includes substances like Palmitoylethanolamide (PEA). This development is part of Clearmind's collaboration with SciSparc Ltd.

Under the collaboration, SciSparc and Clearmind are researching combination therapies that integrate psychedelic molecules with the N-acylethanolamines family, including Palmitoylethanolamide.